BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

Men with suspected prostate cancer will be able to get a diagnosis on the NHS within a day, under “game-changing” new trials.

With the backing of Rishi Sunak, Prostate Cancer UK published a report to the national screening committee back in 2022 in ...

Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...